Longitudinal Olfactory Patterns in Multiple Sclerosis: A Scoping Review and Implication for Use in Management of Disease

Lauren L. Todd, BS; Ram Sivakumar, BS; Sharon G. Lynch, MD; Jennifer H. Diebolt, MD; Jacob White, MLS; and Jennifer A. Villwock, MD

CE INFORMATION

ACTIVITY AVAILABLE ONLINE: To access the article and evaluation online, go to https://www.highmarksce.com/mscare.

TARGET AUDIENCE: The target audience for this activity is physicians, advanced practice clinicians, nursing professionals, and other health care providers involved in the management of patients with multiple sclerosis (MS).

LEARNING OBJECTIVE:
Identify the longitudinal patterns of olfactory dysfunction seen in various stages of multiple sclerosis disease course, as described in recent literature to better recognize olfaction as a dynamic, dependent variable of neurodegeneration that correlates with inflammation and clinical markers and may have a future role in recognizing and monitoring disease activity.

ACCREDITATION:

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Intellisphere, LLC. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the health care team, and learners will receive .5 Interprofessional Continuing Education (IPCE) credit for learning and change.

PHYSICIANS: The CMSC designates this journal-based activity for a maximum of .5 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: The CMSC designates this enduring material for .5 contact hour of nursing continuing professional development (NCPD) (none in the area of pharmacology).

DISCLOSURES: It is the policy of the Consortium of Multiple Sclerosis Centers to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity. For this activity, all relevant disclosures have been mitigated.

Francois Bethoux, MD, editor in chief of the *International Journal of MS Care (IJMSC)*, and **Alissa Mary Willis, MD,** associate editor of *IJMSC*, have disclosed no relevant financial relationships. Author **Jennifer A. Villwock, MD,** has a patent pending for olfactory testing and training methods (AROMA, Affordable Rapid Olfaction Measurement Array). There is no product available for commercial sale. Authors **Sharon G. Lynch, MD; Lauren L. Todd, BS; Ram Sivakumar, BS; Jennifer H. Diebolt, MD;** and **Jacob White, MLS,** have disclosed no relevant financial relationships.

The staff at *IJMSC*, CMSC, and Intellisphere, LLC who are in a position to influence content have disclosed no relevant financial relationships. **Laurie Scudder, DNP, NP,** CMSC continuing education director, has served as a planner and reviewer for this activity. She has disclosed no relevant financial relationships.

METHOD OF PARTICIPATION:
Release Date: May 1, 2023; valid for credit through: May 1, 2024.

To receive CE credit, participants must:
(1) Review the continuing education information, including learning objectives and author disclosures.
(2) Study the educational content.
(3) Complete the evaluation, which is available at https://www.highmarksce.com/mscare.

Statements of Credit are awarded upon successful completion of the evaluation. There is no fee to participate in this activity.

DISCLOSURE OF UNLABELED USE: This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. The CMSC and Intellisphere, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC or Intellisphere, LLC.

DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.

ABSTRACT

BACKGROUND: Although studies regarding multiple sclerosis (MS) and olfactory dysfunction (OD) have been previously described and summarized, there is not a sole review of longitudinal studies regarding the matter. This review examines the existing literature investigating MS and its effect on olfaction. In addition, the role of OD in the diagnosis and prognosis of MS is explored.

METHODS: A scoping review of the literature was performed covering longitudinal studies investigating MS and OD. Systematic searches of PubMed, Google Scholar, Web of Science, Embase, PsycInfo, Cumulative Index to Nursing and Allied Health Literature, AgeLine, and MEDLINE were performed using terms that encompassed MS and olfaction. The aim of this review was to build on the existing literature by summarizing only findings that were demonstrated longitudinally.

RESULTS: Of 6938 articles identified from the search, 9 met the inclusion criteria: longitudinal observation of relapsing-remitting or progressive MS. Olfaction was measured and scored using various testing arrays, and these scores were then correlated with a multitude of clinical markers. Across all studies, patients with MS demonstrated increased OD. Longitudinally, 2 contrasting patterns were identified: (1) clinical markers of acute inflammation correlated with an increased odor threshold and (2) clinical markers of neurodegeneration, or progression of disease, correlated with a decreased ability to discriminate and identify odors.

CONCLUSIONS: These studies suggest that olfaction is a dynamic, dependent variable of neurodegeneration, correlating with inflammation and clinical markers. This opens the door for future exploration of olfaction's relationship with MS diagnosis, characterization, and therapeutic response.

Multiple sclerosis (MS) is an autoimmune, neurologic, degenerative disease that is associated with olfactory dysfunction (OD).[1] Many sources have investigated the connection between olfaction and MS using metrics such as the University of Pennsylvania Smell Identification Test (UPSIT)[1,2] and the Connecticut Chemosensory Clinical Research Center olfactory test[3] to better understand the extent of the deficit. Studies usually compare olfaction in patients with MS vs controls or between patients with MS with different disease durations. Although these studies do connect MS and OD, most do so only via cross-sectional methods. Because MS is a disease with multiple progressive patterns—relapsing-remitting (RRMS), primary progressive, and secondary progressive[4]—the level of OD can be drastically different over time. For example, patients with early-stage MS can have minimal to no loss of olfactory identification or discrimination.[5] Identifying studies that use longitudinal methods of tracking olfaction will not only provide more clarity about the progression of OD but may also reveal a connection between the pattern of OD and various MS biomarkers, such as plaque burden. There may also be a place for olfaction in disease detection and surveillance. Olfactory testing is simple, inexpensive, and can be performed during a normal clinic visit.[6] Olfactory monitoring in patients with MS could serve as a useful marker for early intervention, tracking progression, and response to therapy.

METHODS

This scoping review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. As a scoping review, it was not eligible for registration on PROSPERO, an international prospective register of systematic reviews. The purpose of this scoping review was to evaluate the current literature base rather than to collect and analyze the data from these sources.

Eligibility Criteria

Studies were eligible if they were longitudinal in design with the primary discussion involving OD and diagnosis of MS (**FIGURE S1**, available online at IJMSC.org).

From the Department of Neurology (SGL), Department of Otolaryngology (JHD, JAV), and School of Medicine (LLT, RS), University of Kansas Medical Center, Kansas City, KS, USA; and Welch Medical Library, Johns Hopkins University, Baltimore, MD, USA (JW). *Correspondence*: Lauren L. Todd, BS, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA; email: ltodd3@kumc.edu.

FIGURE. Mean Olfactory Scores Over Time

T, Threshold; D, Discrimination; I, Identification

Note: Data were compiled by and adapted from Bsteh G, Hegen H, Ladstätter F, et al. Change of olfactory function as a marker of inflammatory activity and disability progression in MS. *Mult Scler*. 2019;25(2):267-274. doi:10.1177/1352458517745724

Data Collection

Data extraction was performed by 2 authors (L.L.T., R.S.) using the databases and search terms listed in **TABLE S1**. A shared EndNote database was used to manage the citations. All disagreements were discussed between the 2 authors to arrive at a consensus. Data collected included author, year, journal, title, abstract. After the citations were filtered, they received a full-text review.

RESULTS

The initial search identified 6938 published manuscripts. After duplicates were removed, 5170 manuscripts remained. After titles and abstracts were reviewed, 9 studies met the inclusion criteria and underwent full-text review. The 9 studies observed patients with MS at varying stages over a longitudinal time frame, from 24 weeks to 10 years. Olfactory function was measured in 6 studies using the Sniffin' Sticks protocol, in 1 study using the UPSIT, and in 1 study using the Brief Smell Identification Test. A ninth study monitored brain activity during olfaction to measure function. Specific study qualities are listed in **TABLE S2**. Note that of the 9 selected studies, the 5 authored by Bsteh included patients from a single study group.

Many of the studies correlated these results with clinical markers such as Expanded Disability Status Scale score, serum neurofilament light chain (sNfL) level, disease duration, and death, which are presented in **TABLE S3**.

MS and OD

Participants in the study by Bsteh et al[7] exhibited lower scores in all measures of olfaction/olfactory function (threshold, discrimination, and identification) at every point compared with controls. The difference between discrimination (–0.5; IQR, –1.0, 0.0; $P = .43$) and identification (–1.0; IQR, –1.5, –0.5; $P = .002$) scores from baseline to year 3 showed significant decay. Threshold scores did not decline with increased duration of disease. The evolution of scores between patients and controls is presented in the **FIGURE**.

TABLE 1. Baseline Participant Characteristics

Author	Clinical marker of acute inflammation	Clinical marker of neurodegeneration and progression of disease
Doty et al[9]		Increased plaque numbers in those with decreased UPSIT scores (identification). Subsequent increase in UPSIT score as plaques healed.
Bsteh et al[7,8,12-14]	Increased INL thickness/volume and decreased threshold scores in patients with acute relapse compared with patients who had not relapsed. Significance of this finding decreased as time drew further from relapse.[7,12,13]	Statistically profound correlation between decreased DI scores and decreased gray matter concentration in patients with MS.[8] Increased sNfL levels on 2 occasions correlated with larger decreases in DI scores.[14]
Ciurleo et al[10]	Absent OERPs at baseline were a significant predictor of increased TNR (r_{pb} = −0.34; P = .08) and increased disability (EDSS) (r_{pb} = −0.48; P = .009).	
da Silva et al[15]		Lower BSIT scores at baseline correlated with higher increases in MSSS, ARMSSS, and HRs of death.
Uecker et al[11]		Significant correlation between lower odor discrimination scores in patients with higher rates of relapse.

ARMSSS, Age-Related Multiple Sclerosis Severity Score; BSIT, Brief Identification Smell Test; DI, discrimination and identification; EDSS, Expanded Disability Status Scale; INL, inner nuclear layer; MS, multiple sclerosis; MSSS, Multiple Sclerosis Severity Score; OERP, olfactory event-related potential; sNfL, serum neurofilament light chain; TNR, total number of relapses; UPSIT, University of Pennsylvania Smell Identification Test.

Two studies used neurologic imaging to investigate olfaction.[8,9] In both instances, olfaction was consistently impaired in patients with a more severe degree of change on imaging. Specific findings are listed in **TABLE 1**. Of note, threshold scores were not affected by changes seen on MRI.

Brain activity relating to olfaction was measured using evoked potentials (olfactory event-related potentials [OERPs]) in individuals with disease vs controls.[10] As seen in Table 1, a blunted degree of brain activity at baseline was predictive of a higher number of relapses and furthered disability in those with RRMS. Only 1 group of patients with RRMS had stable, albeit decreased, levels of olfaction over the course of 3 years.[11]

Relapsing-Remitting MS

Two studies of individuals with only RRMS looked at markers of acute inflammation, presence of acute relapse, and increased retinal inner nuclear layer thickness to track disease activity against olfaction.[12,13] Both inflammatory markers dynamically correlated with threshold score (Table 1).

Another clinical marker—sNfL level, a marker of axonal injury—measured higher in individuals with RRMS than in controls. Those with a sustained increase in sNfL measurements displayed a significantly steeper decline in discrimination and identification scores from baseline.[14]

Progressive MS

Only 1 study investigated olfaction in people with progressive MS using degree of disability and length of life.[15] A more severe loss of olfaction correlated with increased disability over time, as measured using the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score. Impaired baseline olfaction

scores were also correlated with higher rates of death in those with progressive MS after 10 years (Table 1).

DISCUSSION

This scoping review sought to identify, review, and interpret the emerging literature on the longitudinal implications of MS on olfaction. A previous meta-analysis described the association between MS and OD with a pooled prevalence of 27.2%.[16] Although beneficial, cross-sectional studies are limited to illustrating a snapshot of olfaction in an unstable disease course. A need for larger, longitudinal studies to delineate this relationship led to a recent increase in prospective studies. This review included 9 studies, with 8 occurring in the past 5 years, that measured olfaction in people with MS at multiple points in time.

Two main patterns were identified from the literature: (1) Clinical markers of short-term inflammation, as measured by the presence of relapse and thickened retinal nerve fiber layer, correlated most with an increased odor threshold in people with MS and, in contrast, (2) clinical markers of neurodegeneration, or axonal injury as measured by the sNfL level, correlated most with a decreased ability to discriminate and identify odors. Table 1 summarizes these findings.

Odor threshold has been used in multiple validated olfactory tests, such as Sniffin' Sticks.[17] To test threshold, butanol is presented to subjects at varying dilutions, with higher scores indicating identification at lower concentrations. The relationship between decreased odor threshold scores and increased inflammatory processes in people with acute, early-stage MS has been demonstrated in cross-sectional research.[18] A similar correlation was supported in the selected longitudinal studies[9,11]; however, the longitudinal findings suggest that

PRACTICE POINTS

Multiple sclerosis is associated with an overall decrease in olfaction.

Odor threshold, or ability to detect an odor, declines and improves with disease activity as measured by clinical markers of acute inflammation.

Odor discrimination and identification are decreased in patients with more progressive disease as measured by plaque burden, disability, and neurodegeneration. ■

threshold may play a more fluid role in early disease. The decline and subsequent improvement of threshold scores mirrored that of acute relapse with gradual incomplete recovery. Other clinical markers of relapse and inflammation, such as development of plaques on MRI and inner nuclear layer thickness, also correlated with the threshold's fluctuation.[9,13] Because odor threshold seems to follow the relapsing and remitting nature of disease symptoms, it could potentially be used to monitor occurrence of relapse.

Akin to odor threshold, discrimination and identification are commonly used in olfactory testing, with identification, such as the UPSIT,[19] being included by most testing arrays used in the selected studies. Cross-sectionally, lower discrimination and identification scores have been correlated with lower Expanded Disability Status Scale and quality of life scores, as well as higher plaque burden.[7] By viewing these qualities of olfaction longitudinally, the reviewed studies demonstrated a correlation between disease progression and decreased discrimination and identification scores. Disease progression was denoted in the reviewed studies through gray matter atrophy and a sustained increase in sNfL level, indicating axonal injury.

Discrimination and identification are important components in what has previously been described as an odor object. Odor objects are created in the piriform cortex through its direct communication with the olfactory bulb. These objects are unique and allow the brain to both identify and discriminate between specific odors.[20] Coincidentally, the piriform cortex lies between the insula

and the amygdala, areas where increased demyelination in people with MS is often noted.[21]

This finding suggests that, unlike threshold, decreased discrimination and identification are more permanent changes and may relate to lasting neuronal damage. In addition, the presence of lowered discrimination and identification scores at baseline was associated with worse outcomes at study conclusion, including increased frequency of relapse, greater disability, and a higher risk ratio of death in those with more progressive disease. Discrimination and identification scores may correlate with these biomarkers due to the possible association between odor discrimination and identification and the presence of demyelination in the piriform cortex's adjacent structures. Future research should investigate this relationship further.

With the predictive value of these scores, there is potential clinical benefit to the early measurement of discrimination, identification, and absence of OERP. In the study by Comi et al,[22] patients with a neurologic event and clinical and MRI evidence suggesting the presence of MS were administered interferon beta within 3 months. Early administration of interferon beta correlated with lower rates of acute relapse, decreased plaque burden, and longer time before clinically definite disease.[22] The olfaction tests used to measure discrimination, identification, and OERP could serve as an additional test alongside clinical symptoms and MRI to identify those at risk for future disease who could benefit from early treatment. In addition, they could be used to help signal evidence of new breakthrough disease that might require treatment change. These tests have the advantage of being simple, inexpensive, and able to be performed in the course of a normal clinic visit, and their results could help inform the need for more complex or expensive testing.

Note there was not an association between MS course and decline in threshold, discrimination, or identification scores in the 2017 study by Uecker et al.[11] These results may have differed from the other studies secondary to a smaller sample size with a lower mean ± SD relapse rate of 0.3 ± 0.5 across 3 years. By mainly observing those with stable disease, they may have been less likely to observe the olfactory changes that we hypothesize to correlate with inflammatory activity and neurodegeneration.

CONCLUSIONS

The findings from the studies included in this review reinforce previous findings demonstrated in cross-sectional studies; however, these findings also build on the existing literature and demonstrate longitudinal olfactory patterns in the MS disease process. Although each study bore different results, 2 main patterns were apparent when comparing the data of all studies: (1) Clinical markers of acute inflammation correlated most

with an increased odor threshold in people with MS and (2) clinical markers of neurodegeneration, or axonal loss, correlated most with a decreased ability to discriminate and identify odors. These findings suggest that there is a potential clinical benefit to using olfaction in the diagnostic and prognostic journey of this fluctuating, expensive, and challenging disease. Future research of olfaction alongside well-known clinical markers is needed to further understand the patterns discussed in this review and to identify and use olfactory testing as an important clinical marker in people with MS. ■

REFERENCES

1. Goverover Y, Chen MH, Costa SL, Chiaravalloti ND, DeLuca J. Smell as a clinical-marker for functional limitations in multiple sclerosis: a pilot study. *Mult Scler Relat Disord*. 2020;46:102508. doi:10.1016/j.msard.2020.102508

2. Hawkes CH, Shephard BC, Kobal G. Assessment of olfaction in multiple sclerosis: evidence of dysfunction by olfactory evoked response and identification tests. *J Neurol Neurosurg Psychiatry*. 1997;63(2):145-151. doi:10.1136/jnnp.63.2.145

3. Atalar AÇ, Erdal Y, Tekin B, Yıldız M, Akdoğan Ö, Emre U. Olfactory dysfunction in multiple sclerosis. *Mult Scler Relat Disord*. 2018;21:92-96. doi:10.1016/j.msard.2018.02.032

4. Klineova S, Lublin FD. Clinical course of multiple sclerosis. *Cold Spring Harb Perspect Med*. 2018;8(9):a028928. doi:10.1101/cshperspect.a028928

5. Batur Caglayan HZ, Irkec C, Nazliel B, Akyol Gurses A, Capraz I. Olfactory functioning in early multiple sclerosis: Sniffin' Sticks Test study. *Neuropsychiatr Dis Treat*. 2016;12:2143-2147. doi:10.2147/NDT.S116195

6. Patel ZM, Wise SK, DelGaudio JM. Randomized controlled trial demonstrating cost-effective method of olfactory training in clinical practice: essential oils at uncontrolled concentration. *Laryngoscope Investig Otolaryngol*. 2017;2(2):53-56. doi:10.1002/lio2.62

7. Bsteh G, Hegen H, Ladstätter F, et al. Change of olfactory function as a marker of inflammatory activity and disability progression in MS. *Mult Scler*. 2019;25(2):267-274. doi:10.1177/1352458517745724

8. Bsteh G, Steiger R, Tuovinen N, et al. Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS. *Mult Scler*. 2020;26(6):706-715. doi:10.1177/1352458519838205

9. Doty RL, Li C, Mannon LJ, Yousem DM. Olfactory dysfunction in multiple sclerosis: relation to longitudinal changes in plaque numbers in central olfactory structures. *Neurology*. 1999;53(4):880-882. doi:10.1212/wnl.53.4.880

10. Ciurleo R, Bonanno L, De Salvo S, et al. Olfactory dysfunction as a prognostic marker for disability progression in multiple sclerosis: an olfactory event related potential study. *PLoS One*. 2018;13(4):e0196006. doi:10.1371/journal.pone.0196006

11. Uecker FC, Olze H, Kunte H, et al. Longitudinal testing of olfactory and gustatory function in patients with multiple sclerosis. *PLoS One*. 2017;12(1):e0170492. doi:10.1371/journal.pone.0170492

12. Bsteh G, Hegen H, Ladstätter F, et al. Transient impairment of olfactory threshold in acute multiple sclerosis relapse. *Mult Scler Relat Disord*. 2018;23:74-77. doi:10.1016/j.msard.2018.05.006

13. Bsteh G, Hegen H, Altmann P, et al. Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis. *Mult Scler J Exp Transl Clin*. 2020;6(3):2055217320945738. doi:10.1177/2055217320945738

14. Bsteh G, Berek K, Hegen H, et al. Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis. *Mult Scler J Exp Transl Clin*. 2019;5(4):2055217319885987. doi:10.1177/2055217319885987

15. da Silva AM, Torres C, Ferreira I, et al. Prognostic value of odor identification impairment in multiple sclerosis: 10-years follow-up. *Mult Scler Relat Disord*. 2020;46:102486. doi:10.1016/j.msard.2020.102486

16. Mirmosayyeb O, Ebrahimi N, Barzegar M, Afshari-Safavi A, Bagherieh S, Shaygannejad V. Olfactory dysfunction in patients with multiple sclerosis; a systematic review and meta-analysis. *PLoS One*. 2022;17(4):e0266492. doi:10.1371/journal.pone.0266492

17. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. *Chem Senses*. 1997;22(1):39-52. doi:10.1093/chemse/22.1.39

18. Bsteh G, Berek K, Hegen H, et al. Smelling multiple sclerosis: different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. *Mult Scler*. 2020;26(1):57-68. doi:10.1177/1352458518814113

19. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. *Physiol Behav*. 1984;32(3):489-502. doi:10.1016/0031-9384(84)90269-5

20. Bekkers JM, Suzuki N. Neurons and circuits for odor processing in the piriform cortex. *Trends Neurosci*. 2013;36(7):429-438. doi:10.1016/j.tins.2013.04.005

21. OuYang Q, Wang Y, Zhang YW, Yu M, Wang X. Change in functional brain activation patterns induced by olfactory stimulation in multiple sclerosis. *Neuropsychiatr Dis Treat*. 2020;16:1451-1458. doi:10.2147/NDT.S252933

22. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet*. 2001;357(9268):1576-1582. doi:10.1016/s0140-6736(00)04725-5